Press Release

– Study provides further validation of the potentially broad utility for CRAC channel inhibitors in inflammatory diseases– Data show that inhibiting store-operated Ca2+ entry (SOCE) with a selective CRAC channel inhibitor reduced IBD severity in murine models LA JOLLA, Calif., [August 9, 2022] – CalciMedica Inc. (“CalciMedica” or the “Company), the CRAC (calcium release-activated calcium) channel company, today …

CalciMedica Announces Publication of Preclinical Data in EMBO Molecular Medicine Supporting the Development of CRAC Channel Inhibitors for Inflammatory Bowel Disease (IBD) Read More »

– Results further support therapeutic potential of Auxora in respiratory diseases and other inflammatory diseases – LA JOLLA, Calif., April 14, 2022 – CalciMedica Inc. (CalciMedica or the Company), the CRAC (calcium release-activated calcium) channel company, today announced the publication of results from the Company’s CARDEA clinical trial, a Phase 2 trial of Auxora in severe COVID-19 …

CalciMedica Announces Publication of Results from CARDEA COVID-19 Study in Critical Care Read More »

Study Supports Development of CRAC Channel Inhibitors for Acute Pancreatitis Study indicates that Orai1 inhibition prevents impaired ductal cell function in acute pancreatitis (AP) Data describes underlying biological mechanisms that may explain key result in a Phase 2a trial of AuxoraTM in patients with AP with systemic inflammatory response syndrome and hypoxemia LA JOLLA, Calif., …

CalciMedica Announces Publication of Peer-Reviewed Paper in The Journal of Physiology Read More »

CARDEA-Plus is designed to evaluate dosing, safety and efficacy of Auxora in combination with both tocilizumab and corticosteroids LA JOLLA, Calif., January 20, 2022 – CalciMedica Inc. (CalciMedica or the Company), the CRAC (calcium release-activated calcium) channel company, today announced the initiation of CARDEA-Plus, a Phase 2b clinical trial being conducted in the United States and Canada, …

CalciMedica Initiates CARDEA-Plus: A Clinical Trial of Auxora™ in Patients with Critical COVID-19 Pneumonia Read More »

LA JOLLA, Calif., November 2, 2021 – CalciMedica Inc. (“CalciMedica” or the “Company), the CRAC channel company, today announced the appointment of Allan L. Shaw to its Board of Directors. “We welcome Allan to our team and are excited to draw on his impressive background in corporate finance, capital markets, strategic transactions, corporate governance and risk …

CalciMedica Strengthens Board of Directors with Appointment of Finance Veteran Allan L. Shaw Read More »

Reduction in time to recovery through day 60 in patients with moderate and severe respiratory failure (primary endpoint analysis) Statistically significant reduction in time to recovery through day 60 in all patients who received study drug (a pre-specified supplementary analysis of the primary endpoint) Statistically significant 56% relative risk reduction in 30-day all-cause mortality secondary …

CalciMedica Reports Topline Data from the AuxoraTM CARDEA Phase 2 COVID-19 Pneumonia Clinical Trial Read More »

Data provides further evidence of the broad potential for CRAC channel inhibitors to benefit patients across multiple disease areas involving the lungs LA JOLLA, Calif., September 9, 2021 – CalciMedica Inc. (“CalciMedica” or the “Company”), the CRAC channel company, today announced the publication of preclinical data validating calcium release-activated calcium (CRAC) channels, P2Y2 receptors, and P2X receptors …

CalciMedica Announces Publication of Preclinical Data in Journal of Immunology Further Validating Calcium Release-Activated Calcium (CRAC) Channels as Drug Targets for Diseases of the Airways Read More »

Data from Phase 2a Study Demonstrated Patients Treated with Auxora Experienced Reduced Severity of Acute Pancreatitis, Less Persistent Systemic Inflammatory Response Syndrome (SIRS) and More Rapid Restoration of Gut Function with Favorable Safety Profile Patient dosing has begun in Phase 2b study in acute pancreatitis; data expected H2 2022 LA JOLLA, Calif., June 2, 2021 …

CalciMedica Publishes Positive Data from Phase 2a Study of Auxora in Patients with Acute Pancreatitis and Announces First Patients Dosed in Phase 2b Study Read More »

Round led by Quark Venture LP and Global Health Sciences (GHS) Fund Funds to support advancement of anti-inflammatory therapy, AuxoraTM, currently being evaluated in severe and critical COVID-19 pneumonia and acute pancreatitis with SIRS Zafi Avnur, Ph.D., chief scientific officer and partner at Quark Venture, joins Board of Directors LA JOLLA, Calif., March 11, 2021 …

CalciMedica Announces $21 Million Series D Financing Read More »

D-dimer levels have been correlated with disease severity and risk of mortality in patients with COVID-19 Treatment with Auxora improved D-dimer levels in patients with severe COVID-19 pneumonia LA JOLLA, Calif., February 2, 2021 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of …

CalciMedica Presents New Clinical Data Demonstrating Improved D-Dimer Biomarker Levels with Auxora™ in Severe COVID-19 Pneumonia at the 50th Critical Care Congress Read More »